Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000, with Q4 revenue at $49.9 million, representing an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [8][20] - Adjusted EBITDA for Q4 was positive at $536,000, marking a significant improvement of approximately $11 million sequentially from Q3, and the first return to positive adjusted EBITDA in four quarters [9][22] - GAAP net loss for Q4 was $63 million, including a $25.8 million non-cash impairment charge, compared to a loss of $46.1 million in Q4 2024 [21] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% when excluding the prior year's CleanCap revenue [20][25] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [20][26] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [25][26] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [21] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809 from 643 a year ago, indicating sustained interest in RNA-based approaches [17] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, increase customer interaction, and deliver better financial results, with a focus on expanding TriLink's role in the mRNA and gene-based therapeutic workflow [7][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing stabilization in the broader tools and biotech environment, with signs of recovery in biopharma funding [16] - The company anticipates total revenue growth of 8%-13% in 2026, with adjusted EBITDA expected to improve by $50 million-$52 million over 2025 [27][28] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [29] - The securities class action lawsuits against the company were dismissed, reflecting positive progress in resolving legal matters [30] Q&A Session Summary Question: Visibility on order volume and growth areas - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating strong customer engagement [34][35] Question: Gross margin expansion details - The gross margin expansion of 1,200 basis points is attributed to $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [41] Question: AI's role in efficiency - The company is utilizing AI through its mRNA Builder platform, which automates the design of optimized RNA constructs, enhancing customer engagement [43] Question: Expectations for 2026 and potential challenges - Management remains optimistic for Q1 and the year, with no significant negative comps expected, and strong customer spending observed [47][50] Question: COVID CleanCap revenue expectations - The company expects $10 million-$20 million in COVID CleanCap revenue for the first half of 2026, with no additional revenue anticipated in the second half [92][94]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [8][20] - Adjusted EBITDA for Q4 was positive at $536,000, marking a significant improvement of approximately $11 million sequentially from Q3, and the first return to positive adjusted EBITDA in four quarters [9][22] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [21] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap comparison [20][25] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [20][26] - For the full year, TriLink revenue was $119.8 million, or 64% of total revenue, while Cygnus revenue increased 5% to $66 million [25][26] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [21] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [17] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, increase customer interaction, and deliver better financial results, with a focus on expanding TriLink's role in the mRNA and gene-based therapeutic workflow [7][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing stabilization in the broader tools and biotech environment, with signs of recovery in biopharma funding [16][18] - The company anticipates total revenue growth of 8%-13% in 2026, with adjusted EBITDA expected to improve by $50 million-$52 million over 2025 [27][28] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [29] - The securities class action lawsuits against the company and certain former executives were dismissed in full [30] Q&A Session Summary Question: Visibility on order volume and growth areas - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating strong customer engagement [33][35] Question: Gross margin expansion details - The gross margin expansion of 1,200 basis points is attributed to $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [41] Question: AI's role in drug discovery and efficiency - The company is utilizing AI through its mRNA Builder platform, which automates the design of optimized RNA constructs, enhancing efficiency in customer workflows [43] Question: Revenue guidance and potential seasonality - Management expressed optimism for Q1, indicating no serious negative comps and a diverse set of customers driving orders [47][50] Question: COVID CleanCap revenue expectations - The company expects $10 million-$20 million in COVID CleanCap revenue for the first half of 2026, with no additional revenue anticipated in the second half [92][94] Question: Traction in new product lines - The ModTail technology has seen strong early adoption, generating over $1 million in orders, and the company plans to launch more kits in 2026 [98]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [6][19] - Adjusted EBITDA for Q4 was positive at $536,000, marking the first return to positive adjusted EBITDA in four quarters, an improvement of approximately $11 million sequentially from Q3 [7][21] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [20] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap revenue [19][24] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [19][25] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [24][25] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [20] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [15] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, and enhance customer engagement, positioning TriLink as a key player in the mRNA and gene-based therapeutic workflow [6][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [12][14] - The company is focused on operational discipline and cost-saving measures, exceeding initial targets and positioning for revenue growth and positive cash flow in 2026 [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing improved visibility and strong order volumes, particularly in GMP consumables and larger orders in Discovery [14][34] - The broader biotech environment appears to be stabilizing, with signs of recovery in biopharma funding, although smaller players remain cautious [14][16] - Customer feedback indicates a constructive FDA stance in areas like cell and gene therapy, which is expected to support ongoing program advancements [17] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [28] - The securities class action lawsuits against the company and certain former executives were dismissed in full [29] Q&A Session Summary Question: Visibility and order volume tracking for 2026 - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating confidence in forecasts for the year [33][34] Question: Demand factors for GMP consumables - Growth in GMP consumables is attributed to a broad set of customers rather than a single program, reflecting a diverse customer base [35][36] Question: Gross margin expansion details - Gross margin expansion of 1,200 basis points is driven by $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [39] Question: Current mRNA pipeline trends - Management estimates about a third market share in the mRNA ecosystem, with growth expected as more programs transition from discovery to GMP [60][64] Question: COVID CleanCap revenue expectations - The company expects total COVID CleanCap revenue of $10 million-$20 million for 2026, all anticipated in the first half of the year [91][93]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $41.6 million, down from $69 million in Q3 2024, representing a decline of approximately 40% [15][16] - Adjusted EBITDA for Q3 2025 was a negative $10.8 million compared to a positive $16.2 million in Q3 2024 [16][23] - GAAP net loss before non-controlling interest was $45.1 million for Q3 2025, compared to a loss of $172.5 million in Q3 2024, which included a goodwill impairment charge of $154.2 million [16][23] Business Line Data and Key Metrics Changes - Biologics Safety Testing (BST) revenue was $16.3 million, growing 7% year-over-year, while Nucleic Acid Products (NAP) revenue was $25.4 million, declining 53% year-over-year [3][19] - The base NAP business, excluding GMP COVID CleanCap, was down 29% year-over-year [16][19] - Adjusted EBITDA for BST was $10.5 million, with an adjusted EBITDA margin of 64.8% [19][20] Market Data and Key Metrics Changes - Revenue by geography: 60% from North America, 19% from EMEA, 12% from Asia-Pacific (excluding China), 8% from China, and 1% from Latin and Central America [15][16] - Strength in BST was primarily from the U.S. and European markets, which grew 8% and 17% year-over-year, respectively [5][19] - China market showed weakness, with a reported decline of 12% [57][60] Company Strategy and Development Direction - The company aims to achieve positive adjusted EBITDA and cash flow in 2026, with a focus on operational excellence and revenue growth [4][13] - A strategic realignment and cost reduction initiative is underway, targeting over $50 million in annualized expense reductions [4][21] - The introduction of new technologies like MODTAIL is expected to broaden the customer base and drive future revenue, particularly in CAR T and oncology applications [9][66] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Q4 performance, citing strong order velocity and visibility into future growth [18][48] - The company anticipates closing 2025 with revenue of approximately $185 million, implying an 18% growth in Q4 over Q3 [22][23] - Management noted that the funding environment for discovery remains challenging but is showing signs of stabilization [43][44] Other Important Information - The company has stabilized operations and significantly reduced expenses, strengthening its balance sheet [4][21] - The launch of the mRNA Builder platform has doubled the number of orders placed, enhancing operational efficiency [11][68] Q&A Session Summary Question: Anticipated revenue contribution from COVID CleanCap in 2026 - Management indicated that the $10-$20 million revenue contribution is based on a combination of orders in hand and ongoing customer discussions [26] Question: Cost savings breakdown for Q4 and next year - Cost savings are expected to come from various categories, with approximately 40-50% from labor cost reductions and a roughly 50/50 split between COGS and OpEx [27] Question: Key findings from the strategic review - The company was found to be over-structured, and the restructuring has led to improved operational efficiency and engagement from the leadership team [32][33] Question: Performance of BST and regional strength - Management confirmed strength in the U.S. and Europe, while China remains weak, but there are signs of improvement in funding [34][35] Question: Gross margin expectations for Q4 and 2026 - Management expects improvements in gross margin due to cost reductions and a favorable product mix in Q4 [37][38] Question: Confidence in GMP business excluding COVID - Management expressed high confidence in Q4 and 2026, citing strong order visibility and binding purchase commitments [47][49]